Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1996-1-24
|
| pubmed:abstractText |
Studies showed that endothelin-1 (ET-1) was increased in the acute myocardial infarction (AMI). Experimental studies reported that captopril was able to reduce ET-1 secretion, and that ET-1 was increased during reperfusion. This study was aimed to verify if captopril was able to reduce plasma ET-1 during thrombolysis in AMI. Seventy-three patients, hospitalized for suspected AMI within 4 h from the onset of symptoms suitable for thrombolysis (1st episode), Killip class 1-2, were randomized (double blind) into two groups: group 1 (37 pts), 8 F/29 M, received captopril, 6.25 mg, orally 15 min before thrombolysis. Group 2: (36 pts) 8 F/28 M, received placebo before thrombolysis. All patients met the reperfusion criteria. Plasma ET-1 were checked on admission, at 1 h and at 2 h, after starting thrombolysis. Group 1 contained ten unstable angina, 17 anterior and ten inferior AMIs. Group 2 contained ten unstable angina, 16 anterior and ten inferior AMIs. Mean concentrations of ET-1: Unstable angina: group 1, basal--4.56, at 1 h--4.47, 2 h--5.89 pg/ml; group 2: basal--4.17, at 1 h--4.59, 2 h--5.24 pg/ml. Inferior AMI: group 1: basal--6.87, 1 h--7.75, 2 h--8.47; group 2: basal--6.34, 1 h--6.68, 2 h--7.98 pg/ml. Anterior AMI: group 1: basal--7.17, 1 h--7.93, 2 h--10.76 pg/ml (between basal and 2-h samples P < 0.05); group 2: basal--7.46, 1 h--7.51, 2 h--10.74 pg/ml. Differences between the two groups were not significant. Our data suggest that captopril does not affect plasma ET-1 during thrombolysis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme...,
http://linkedlifedata.com/resource/pubmed/chemical/Captopril,
http://linkedlifedata.com/resource/pubmed/chemical/Creatine Kinase,
http://linkedlifedata.com/resource/pubmed/chemical/Endothelins,
http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes,
http://linkedlifedata.com/resource/pubmed/chemical/Placebos,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Plasminogen Activator
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0167-5273
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
51
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
131-5
|
| pubmed:dateRevised |
2006-7-12
|
| pubmed:meshHeading |
pubmed-meshheading:8522408-Administration, Oral,
pubmed-meshheading:8522408-Angina, Unstable,
pubmed-meshheading:8522408-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:8522408-Blood Pressure,
pubmed-meshheading:8522408-Captopril,
pubmed-meshheading:8522408-Creatine Kinase,
pubmed-meshheading:8522408-Double-Blind Method,
pubmed-meshheading:8522408-Electrocardiography,
pubmed-meshheading:8522408-Endothelins,
pubmed-meshheading:8522408-Female,
pubmed-meshheading:8522408-Heart Rate,
pubmed-meshheading:8522408-Humans,
pubmed-meshheading:8522408-Isoenzymes,
pubmed-meshheading:8522408-Male,
pubmed-meshheading:8522408-Myocardial Infarction,
pubmed-meshheading:8522408-Myocardial Reperfusion,
pubmed-meshheading:8522408-Placebos,
pubmed-meshheading:8522408-Recombinant Proteins,
pubmed-meshheading:8522408-Thrombolytic Therapy,
pubmed-meshheading:8522408-Time Factors,
pubmed-meshheading:8522408-Tissue Plasminogen Activator
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Captopril does not affect plasma endothelin-1 during thrombolysis and reperfusion.
|
| pubmed:affiliation |
Division of Cardiology, G.F. Ingrassia Hospital, Palermo, Italy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|